|Bid||26.09 x 280000|
|Ask||27.01 x 190000|
|Day's range||26.08 - 26.08|
|52-week range||23.43 - 79.90|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Twist Bioscience ( NASDAQ:TWST ) Full Year 2022 Results Key Financial Results Revenue: US$203.6m (up 54% from FY 2021...
Twist Bioscience (TWST) delivered earnings and revenue surprises of 28.91% and 0.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Shares of Twist Bioscience (NASDAQ: TWST) were crashing this week, plunging 37.2% as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. The steep decline came after Scorpion Capital announced on Tuesday that it was short-selling the stock and released a scathing online report about the synthetic DNA maker. Scorpion accused Twist Bioscience of being "a cash-burning inferno that is not a going concern."